Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Educational Dinner Meeting

MODULE 1: Management Approaches for Nonmetastatic Prostate Cancer

• Indications for and selection of androgen deprivation therapy (ADT) for patients with prostate cancer
• Key efficacy and safety data with and FDA-approved indications for relugolix; optimal integration into practice
• Findings from the STAMPEDE trial of abiraterone and prednisolone with or without enzalutamide in combination with ADT for men with high-risk nonmetastatic prostate cancer; current clinical implications
• Major efficacy and safety results and practical implications of the Phase III PRESTO study evaluating ADT intensification with apalutamide with or without abiraterone for patients with biochemically recurrent prostate cancer and a rapid PSA doubling time
• Other ongoing Phase III trials evaluating secondary hormonal agents for high-risk localized or locally advanced prostate cancer
• Long-term efficacy and safety outcomes with apalutamide, enzalutamide or darolutamide for patients with nonmetastatic castration-resistant prostate cancer (CRPC)
• Clinical, biologic and practical factors in the selection of enzalutamide, apalutamide or darolutamide for patients with nonmetastatic CRPC

MODULE 2: : Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

• Key clinical, biologic and practical factors in the selection of systemic therapy for patients with mHSPC
• Long-term efficacy and safety data, including overall survival findings, with docetaxel, abiraterone, enzalutamide and apalutamide, each in combination with ADT, for mHSPC
• Major findings from the Phase III PEACE-1 study of ADT with or without docetaxel, with or without local radiation therapy, with or without abiraterone and prednisone for mHSPC
• Published efficacy and safety results from the Phase III ARASENS trial of darolutamide in combination with docetaxel and ADT for mHSPC; FDA-approved indication and optimal incorporation into management algorithms
• Outcomes observed in the subset of patients who received docetaxel in addition to enzalutamide and ADT in the Phase III ENZAMET study
• Ongoing Phase III trials attempting to further define the optimal management of mHSPC (eg, TALAPRO-3, CYCLONE 3, PSMAddition)

MODULE 3: Therapeutic Considerations for Patients with Newly Diagnosed Metastatic CRPC (mCRPC)

• Key clinical and biologic factors in the selection of therapy for patients with newly diagnosed mCRPC; impact of earlier use of chemotherapy and secondary hormonal therapy on current treatment algorithms
• Key findings from clinical trial and real-world data sets exploring the efficacy and safety of sipuleucel-T for mCRPC; effect on outcomes of patient age, race, PSA level and other factors
• Optimal patient selection for treatment with sipuleucel-T; importance of early identification of appropriate candidates
• Biologic basis for combining PARP inhibitors with antiandrogen therapies for prostate cancer; rationale for the activity of these combinations as front-line therapy in patients without HRR gene mutations
• Available and emerging data with PARP inhibitors combined with secondary hormonal agents for previously untreated mCRPC (eg, from the PROpel, MAGNITUDE and TALAPRO-2 trials)
• Other ongoing Phase III studies evaluating PARP inhibitors in combination with androgen receptor (AR)-targeted agents for mCRPC and mHSPC
• Biologic rationale for the evaluation of CDK4/6 inhibitors in patients with mCRPC
• Design, eligibility criteria and primary and secondary endpoints of the Phase II/III CYCLONE 2 trial evaluating first-line abiraterone and prednisone with or without abemaciclib for mCRPC; estimated study completion date

MODULE 4: Contemporary Management of mCRPC in Patients Harboring an HRR Gene Alteration

• Incidence and clinical implications of BRCA1/2 and other HRR abnormalities (eg, ATM, PALB2, CDK12) in patients with prostate cancer
• Mechanistic similarities and differences between approved (eg, olaparib, rucaparib) and investigational (eg, talazoparib, niraparib) PARP inhibitors with documented activity in patients with mCRPC; implications for activity and tolerability
• Available data with PARP inhibitor monotherapy for patients with mCRPC (eg, from the PROfound, TRITON2, TRITON3, GALAHAD and TALAPRO-1 trials)
• FDA-approved indications for olaparib and rucaparib for mCRPC and optimal integration into management algorithms
• Key findings from the Phase III PROpel and MAGNITUDE trials for patients with HRR gene alterations; ramifications for current and future practice
• Implications of emerging findings from TALAPRO-2 for the management of mCRPC in patients with HRR gene mutations

MODULE 5: Current and Emerging Strategies in the Treatment of Recurrent mCRPC

• Available data with, ongoing evaluation of and patient selection for treatment with radium-223 chloride
• Clinical relevance of PSMA expression in prostate cancer; mechanism of action of the novel radioligand ¹⁷⁷Lu-PSMA-617
• Key efficacy and safety findings from the Phase III VISION study evaluating ¹⁷⁷Lu-PSMA-617 for patients with progressive PSMA-positive mCRPC; FDA approval and optimal incorporation into management algorithms
• Design, eligibility criteria and emerging findings from the Phase III PSMAfore trial comparing ¹⁷⁷Lu-PSMA-617 to a change in AR-directed therapy for patients with mCRPC previously treated with an alternate AR pathway inhibitor but not exposed to taxane-containing chemotherapy; implications for therapeutic sequencing
• Spectrum, frequency and management of toxicities associated with ¹⁷⁷Lu-PSMA-617
• Major efficacy and safety findings from the CARD study and other recently reported trials (eg, OSTRICh, CABASTY) investigating cabazitaxel for mCRPC
• Appropriate integration of cabazitaxel into current mCRPC treatment algorithms and practical considerations for its use
• Clinical activity of cabozantinib in patients with mCRPC; preliminary findings from the mCRPC cohort of the Phase Ib COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab
• Design, eligibility criteria and key efficacy and safety endpoints of the Phase III CONTACT-02 trial examining the role of cabozantinib/atezolizumab in therapy for mCRPC
• Other promising novel agents and strategies under investigation for mCRPC

 

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

​ There is no fee to participate in this hybrid event. For the in-person symposium in Chicago preregistration is required as seating is limited.
​ ​ To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.